Skip to main content
. 2012 Mar 21;7(3):e33682. doi: 10.1371/journal.pone.0033682

Table 8. Genotype-phenotype associations of the PTPN2 SNP rs7234029 in UC patients.

PTPN2 SNP rs7234029 AA (n = 220) AG (n = 83) GG (n = 11) PG ORG [95% CI]
Gender (n = 314)
Male 119 (54.1%) 42 (50.6%) 5 (45.5%) 0.506 1.18 [0.73–1.91]
Female 101 (45.9%) 41 (49.4%) 6 (54.5%)
Age at diagnosis (yrs) (n = 298)
Mean ± SD 29.95±14.90 26.32±13.49 30.50±12.70 0.401 1.24 [0.75–2.05]
Range 3–81 2–73 14–57
Age at diagnosis (n = 298)
<16 years (A1) (n = 57) 37 (17.5%) 19 (25.0%) 1 (10.0%) 0.558 1.21 [0.64–2.26] (A1 vs. A2)
17–40 years (A2) (n = 181) 125 (59.0%) 49 (64.5%) 7 (70.0%) 3.47×10−2 2.24 [1.06–4.73] (A2 vs. A3)
>40 years (A3) (n = 60) 50 (23.6%) 8 (10.5%) 2 (20.0%) 2.51×10−2 2.70 [1.13–6.45] (A1 vs. A3)
BMI (kg/m2) (n = 207)
Mean ± SD 23.97±4.66 24.10±4.26 22.90±3.18 0.975 0.99 [0.54–1.82]
Range 15–54 15–36 20–29
Location (n = 258)
Proctitis (E1) (n = 24) 13 (7.2%) 11 (16.4%) 0 (0%) 7.75×10−2 2.15 [0.92–5.05]
Left-sided UC (E2) (n = 96) 71 (39.2%) 20 (29.9%) 5 (50.0%) 0.305 0.74 [0.42–1.31]
Extensive UC (E3) (n = 138) 97 (53.6%) 36 (53.7%) 5 (50.0%) 0.960 0.99 [0.58–1.68]
Extra-intestinal manifestations (n = 188) no: 87 (66.4%) 33 (63.5%) 3 (60.0%) 0.666 1.15 [0.60–2.21]
yes: 44 (33.6%) 19 (36.5%) 2 (40.0%)
Use of immunosuppressive agents (n = 266) no: 50 (26.5%) 15 (22.4%) 1 (10.0%) 0.332 1.37 [0.72–2.60]
yes: 139 (73.5%) 52 (77.6%) 9 (90.0%)
Abscesses (n = 238) no: 161 (97.0%) 58 (92.1%) 7 (77.8%) 3.94×10−2 3.47 [1.06–11.32]
yes: 5 (3.0%) 5 (7.9%) 2 (22.2%)

PG: p-value for association comparing carriers of the G-allele to individuals homozygous for A. Association results for age at diagnosis and BMI are based on median split. Uncorrected p-values<0.05 are depicted in bold. None of the p-values remained significant after Bonferroni correction for multiple testing (number of hypothesis tested: n = 12, resulting in a significance threshold of p<4.167×10−3).